New Alzheimer’s drug that targets cause rather than symptoms approved by US regulator

US

US regulators could approve the first new drug to treat Alzheimer’s in more than a decade, possibly paving the way for it to be used in the UK.

The Food and Drug Administration (FDA) is due to decide on Monday whether to approve Biogen’s aducanumab drug for use in the US.

Aducanumab targets amyloid – plaque that builds up in the brains of people with Alzheimer’s – helping to slow the onset of the condition.

It is the first treatment to target the cause of the disease, as existing ones only help to ease symptoms.

If approved, it could lead other pharmaceutical companies to create similar drugs and the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), to consider it for use in Britain.

Drugs company Biogen says that 1.5 million Americans would be eligible for the new drug, which is administered via infusion.

In the UK it could help the estimated 850,000 people living with the disease.

MPs have launched an investigation into the possible link between head injuries in sport and neurodegenerative diseases after campaigns by footballers and rugby players.

Articles You May Like

As Biden weighs a federal gas tax holiday, here’s what that could mean for prices at the pump
Microbes Found Thriving in a Low-Oxygen, Super-Salty, Sub-Zero Spring in Canadian Arctic
How much money do gas tax holidays actually save drivers? What we know, based on 3 states that put temporary suspensions in place
Quick Charge Podcast: June 20, 2022
Elon Musk’s daughter applies to change name to cut ties with father